奧利司他 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "奧利司他" in Chinese language version.

refsWebsite

Global rank Chinese rank

17web.archive.org

1^st place

12nih.gov

4^th place

5^th place

8doi.org

2^nd place

23^rd place

2archive.org

6^th place

4^th place

2worldcat.org

5^th place

12^th place

1kgh.com.tw

low place

1udn.com

392^nd place

10^th place

1emedtv.com

low place

1legislation.gov.au

6,658^th place

low place

1usatoday.com

41^st place

182^nd place

1fda.gov.tw

low place

1,125^th place

1info.gov.hk

2,665^th place

114^th place

1nhs.uk

1,989^th place

2,409^th place

1archive-it.org

910^th place

767^th place

1bu.edu

2,120^th place

3,098^th place

1rocheusa.com

low place

1scielo.br

1,606^th place

2,599^th place

1fda.gov

447^th place

581^st place

1ama-assn.org

3,257^th place

3,896^th place

1bmj.com

1,226^th place

890^th place

1nytimes.com

7^th place

31^st place

1nejm.org

2,374^th place

1,457^th place

1mhra.gov.uk

low place

ama-assn.org

archinte.ama-assn.org

存档副本. [2011-04-12]. （原始内容存档于2011-08-31）.

archive-it.org

wayback.archive-it.org

FDA Approves alli (orlistat 60 mg capsules) Over-The-Counter (PDF) (新闻稿). PRNewswire. 7 February 2007 [8 April 2007]. （原始内容 (PDF)存档于2007年8月24日）.

archive.org

Zhi J, Melia AT, Eggers H, Joly R, Patel IH. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol. 1995, 35 (11): 1103–8. PMID 8626884.
Zhi J, Moore R, Kanitra L, Mulligan TE. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharmacol. 2003, 43 (4): 428–35. PMID 12723464. doi:10.1177/0091270003252236.

bmj.com

Douglas, Ian J; Julia Langham; Krishnan Bhaskaran; Ruth Brauer; Liam Smeeth. Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink. BMJ. 2013, 346: f1936 [2018-04-13]. PMC 3624963 . PMID 23585064. doi:10.1136/bmj.f1936. （原始内容存档于2021-01-16）.

bu.edu

bumc.bu.edu

FDA Approves alli (orlistat 60 mg capsules) Over-The-Counter (PDF) (新闻稿). PRNewswire. 7 February 2007 [8 April 2007]. （原始内容 (PDF)存档于2007年8月24日）.

doi.org

Barbier, Pierre; Schneider, Fernand. Syntheses of Tetrahydrolipstatin and Absolute Configuration of Tetrahydrolipstatin and Lipstatin. Helvetica Chimica Acta. 1987-02-04, 70 (1): 196–202. ISSN 0018-019X. doi:10.1002/hlca.19870700124.
Mancini MC, Halpern A. Pharmacological treatment of obesity. Arq Bras Endocrinol Metab. 2006, 50 (2): 377–89. PMID 16767304. doi:10.1590/S0004-27302006000200024. Free full text with registration （页面存档备份，存于互联网档案馆）
Douglas, Ian J; Julia Langham; Krishnan Bhaskaran; Ruth Brauer; Liam Smeeth. Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink. BMJ. 2013, 346: f1936 [2018-04-13]. PMC 3624963 . PMID 23585064. doi:10.1136/bmj.f1936. （原始内容存档于2021-01-16）.
Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999, 281 (3): 235–42. PMID 9918478. doi:10.1001/jama.281.3.235.
J. A. Menendez; L. Vellon; R. Lupu. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Annals of Oncology. 2005, 16 (8): 1253–1267. PMID 15870086. doi:10.1093/annonc/mdi239.
Garcia S, da Costa Barros L, Turatti A, Martinello F, Modiano P, Ribeiro-Silva A, de Oliveira Vespúcio M, Uyemura S. The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. Cancer Lett. 2006, 240 (2): 221–4. PMID 16377080. doi:10.1016/j.canlet.2005.09.011.
Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H, Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer (PDF). N Engl J Med. 1998, 339 (18): 1277–84 [2018-04-13]. PMID 9791143. doi:10.1056/NEJM199810293391803. （原始内容存档于2018-04-13）.
Zhi J, Moore R, Kanitra L, Mulligan TE. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharmacol. 2003, 43 (4): 428–35. PMID 12723464. doi:10.1177/0091270003252236.

emedtv.com

weight-loss.emedtv.com

Orlistat side effects. [2018-04-12]. （原始内容存档于2020-08-01）.

fda.gov

FDA Drug Safety Communication: Completed safety review of Xenical/Alli (orlistat) and severe liver injury. fda.gov. [2018-04-13]. （原始内容存档于2019-04-24）.

fda.gov.tw

衛署藥輸字第025135號. [2018-04-12]. （原始内容存档于2019-08-15）.

info.gov.hk

安全使用含奧利司他的藥物. [2010-05-29]. （原始内容存档于2019-09-02）.

kgh.com.tw

漫談減肥和藥物治療. 郭綜合醫院藥劑科. [2010-06-25]. （原始内容存档于2020-02-18）.

legislation.gov.au

POISON STANDARD JUNE 2017. [2018-04-12]. （原始内容存档于2020-12-13）.

mhra.gov.uk

Orlistat: theoretical interaction with antiretroviral HIV medicines. MHRA. 13 March 2014 [16 November 2014]. （原始内容存档于2014-11-29）.

nejm.org

Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H, Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer (PDF). N Engl J Med. 1998, 339 (18): 1277–84 [2018-04-13]. PMID 9791143. doi:10.1056/NEJM199810293391803. （原始内容存档于2018-04-13）.

nhs.uk

Treating Obesity. NHS. [13 July 2013]. （原始内容存档于2017-10-13）.

nih.gov

ncbi.nlm.nih.gov

Zhi J, Melia AT, Eggers H, Joly R, Patel IH. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol. 1995, 35 (11): 1103–8. PMID 8626884.
{{Torgerson J, Hauptman J, Boldrin M, Sjöström L (2004). "XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients". Diabetes Care. 27 (1): 155–61. doi:10.2337/diacare.27.1.155.PMID 14693982}}
[Torgerson J, Hauptman J, Boldrin M, Sjöström L (2004). "XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients". Diabetes Care. 27 (1): 155–61. doi:10.2337/diacare.27.1.155. PMID 14693982.]
[Siebenhofer, A; Jeitler, K; Horvath, K; Berghold, A; Siering, U; Semlitsch, T (28 March 2013). "Long-term effects of weight-reducing drugs in hypertensive patients". The Cochrane Database of Systematic Reviews (3): CD007654. doi:10.1002/14651858.CD007654.pub3. PMID 23543553.]
Mancini MC, Halpern A. Pharmacological treatment of obesity. Arq Bras Endocrinol Metab. 2006, 50 (2): 377–89. PMID 16767304. doi:10.1590/S0004-27302006000200024. Free full text with registration （页面存档备份，存于互联网档案馆）
Douglas, Ian J; Julia Langham; Krishnan Bhaskaran; Ruth Brauer; Liam Smeeth. Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink. BMJ. 2013, 346: f1936 [2018-04-13]. PMC 3624963 . PMID 23585064. doi:10.1136/bmj.f1936. （原始内容存档于2021-01-16）.
Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999, 281 (3): 235–42. PMID 9918478. doi:10.1001/jama.281.3.235.
J. A. Menendez; L. Vellon; R. Lupu. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Annals of Oncology. 2005, 16 (8): 1253–1267. PMID 15870086. doi:10.1093/annonc/mdi239.
Garcia S, da Costa Barros L, Turatti A, Martinello F, Modiano P, Ribeiro-Silva A, de Oliveira Vespúcio M, Uyemura S. The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. Cancer Lett. 2006, 240 (2): 221–4. PMID 16377080. doi:10.1016/j.canlet.2005.09.011.
Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H, Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer (PDF). N Engl J Med. 1998, 339 (18): 1277–84 [2018-04-13]. PMID 9791143. doi:10.1056/NEJM199810293391803. （原始内容存档于2018-04-13）.
Zhi J, Moore R, Kanitra L, Mulligan TE. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharmacol. 2003, 43 (4): 428–35. PMID 12723464. doi:10.1177/0091270003252236.
Sjöström, L.; Rissanen, A.; Andersen, T.; Boldrin, M.; Golay, A.; Koppeschaar, H. P.; Krempf, M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet (London, England). 1998-07-18, 352 (9123): 167–172 [2018-04-13]. ISSN 0140-6736. PMID 9683204. （原始内容存档于2019-08-13）.

nytimes.com

Kolata, Gina. Obesity Drug Can Lead to Modest Weight Loss, Study Finds. The New York Times. 20 January 1999 [11 December 2007]. （原始内容存档于2019-08-13）.

rocheusa.com

Roche Pharmaceuticals. Xenical (PDF). Roche. July 2008 [19 February 2007]. （原始内容 (PDF)存档于2007-02-08）.

scielo.br

Mancini MC, Halpern A. Pharmacological treatment of obesity. Arq Bras Endocrinol Metab. 2006, 50 (2): 377–89. PMID 16767304. doi:10.1590/S0004-27302006000200024. Free full text with registration （页面存档备份，存于互联网档案馆）

udn.com

免處方首例康孅伴減肥藥下月開賣. 聯合報. 2010-06-25 [2010-06-25]. （原始内容存档于2010-06-28）.

usatoday.com

usatoday30.usatoday.com

"FDA OKs First Nonprescription Diet Pill. [2018-04-12]. （原始内容存档于2014-01-08）.

web.archive.org

漫談減肥和藥物治療. 郭綜合醫院藥劑科. [2010-06-25]. （原始内容存档于2020-02-18）.
免處方首例康孅伴減肥藥下月開賣. 聯合報. 2010-06-25 [2010-06-25]. （原始内容存档于2010-06-28）.
Orlistat side effects. [2018-04-12]. （原始内容存档于2020-08-01）.
POISON STANDARD JUNE 2017. [2018-04-12]. （原始内容存档于2020-12-13）.
"FDA OKs First Nonprescription Diet Pill. [2018-04-12]. （原始内容存档于2014-01-08）.
衛署藥輸字第025135號. [2018-04-12]. （原始内容存档于2019-08-15）.
安全使用含奧利司他的藥物. [2010-05-29]. （原始内容存档于2019-09-02）.
Treating Obesity. NHS. [13 July 2013]. （原始内容存档于2017-10-13）.
Roche Pharmaceuticals. Xenical (PDF). Roche. July 2008 [19 February 2007]. （原始内容 (PDF)存档于2007-02-08）.
Mancini MC, Halpern A. Pharmacological treatment of obesity. Arq Bras Endocrinol Metab. 2006, 50 (2): 377–89. PMID 16767304. doi:10.1590/S0004-27302006000200024. Free full text with registration （页面存档备份，存于互联网档案馆）
FDA Drug Safety Communication: Completed safety review of Xenical/Alli (orlistat) and severe liver injury. fda.gov. [2018-04-13]. （原始内容存档于2019-04-24）.
存档副本. [2011-04-12]. （原始内容存档于2011-08-31）.
Douglas, Ian J; Julia Langham; Krishnan Bhaskaran; Ruth Brauer; Liam Smeeth. Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink. BMJ. 2013, 346: f1936 [2018-04-13]. PMC 3624963 . PMID 23585064. doi:10.1136/bmj.f1936. （原始内容存档于2021-01-16）.
Kolata, Gina. Obesity Drug Can Lead to Modest Weight Loss, Study Finds. The New York Times. 20 January 1999 [11 December 2007]. （原始内容存档于2019-08-13）.
Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H, Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer (PDF). N Engl J Med. 1998, 339 (18): 1277–84 [2018-04-13]. PMID 9791143. doi:10.1056/NEJM199810293391803. （原始内容存档于2018-04-13）.
Orlistat: theoretical interaction with antiretroviral HIV medicines. MHRA. 13 March 2014 [16 November 2014]. （原始内容存档于2014-11-29）.
Sjöström, L.; Rissanen, A.; Andersen, T.; Boldrin, M.; Golay, A.; Koppeschaar, H. P.; Krempf, M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet (London, England). 1998-07-18, 352 (9123): 167–172 [2018-04-13]. ISSN 0140-6736. PMID 9683204. （原始内容存档于2019-08-13）.

worldcat.org

Barbier, Pierre; Schneider, Fernand. Syntheses of Tetrahydrolipstatin and Absolute Configuration of Tetrahydrolipstatin and Lipstatin. Helvetica Chimica Acta. 1987-02-04, 70 (1): 196–202. ISSN 0018-019X. doi:10.1002/hlca.19870700124.
Sjöström, L.; Rissanen, A.; Andersen, T.; Boldrin, M.; Golay, A.; Koppeschaar, H. P.; Krempf, M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet (London, England). 1998-07-18, 352 (9123): 167–172 [2018-04-13]. ISSN 0140-6736. PMID 9683204. （原始内容存档于2019-08-13）.